CTi Biopharma Corp Top Management
CTICDelisted Stock | USD 9.09 0.00 0.00% |
CTi Biopharma employs about 127 people. The company is managed by 7 executives with a total tenure of roughly 8 years, averaging almost 1.0 years of service per executive, having 18.14 employees per reported executive. Evaluation of CTi Biopharma's management performance can provide insight into the firm performance.
David Kirske President CFO, Executive Vice President |
CTi |
CTi Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2858) % which means that it has lost $0.2858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1875) %, meaning that it created substantial loss on money invested by shareholders. CTi Biopharma's management efficiency ratios could be used to measure how well CTi Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.CTi Biopharma Workforce Comparison
CTi Biopharma Corp is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,631. CTi Biopharma holds roughly 127 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.91) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.74) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.74. CTi Biopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CTi Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on CTi Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CTi Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Reed Tuckson over a year ago Acquisition by Reed Tuckson of 80000 shares of CTi Biopharma subject to Rule 16b-3 | ||
Reed Tuckson over a year ago Bona fide gift to Reed Tuckson of 43785 shares of CTi Biopharma subject to Section 16 |
CTi Biopharma Notable Stakeholders
A CTi Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CTi Biopharma often face trade-offs trying to please all of them. CTi Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CTi Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David Kirske | CFO, Executive Vice President | Profile | |
Ed Bell | Director - Investor Relations | Profile | |
Jennifer Smith | VP Biometrics | Profile | |
James Fong | Ex Officer | Profile | |
Bruce Bennett | VP Operations | Profile | |
John Volpone | Ex Staff | Profile | |
MBA MD | CEO and President | Profile |
About CTi Biopharma Management Performance
The success or failure of an entity such as CTi Biopharma Corp often depends on how effective the management is. CTi Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CTi management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CTi management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Cti Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.
Please note, the presentation of CTi Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CTi Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CTi Biopharma's management manipulating its earnings.
CTi Biopharma Workforce Analysis
Traditionally, organizations such as CTi Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CTi Biopharma within its industry.CTi Biopharma Manpower Efficiency
Return on CTi Biopharma Manpower
Revenue Per Employee | 424.8K | |
Revenue Per Executive | 7.7M | |
Net Loss Per Employee | 732.2K | |
Net Loss Per Executive | 13.3M | |
Working Capital Per Employee | 143.8K | |
Working Capital Per Executive | 2.6M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |